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Background: Omega-3 fatty acids are important in treatment of severe primary hypertriglyceridemia (HTG). In 15
patients with severe primary HTG (TG >500 mg/dl despite conventional TG lowering therapy), we assessed
efficacy-safety of sequential monthly treatment with Lovaza, 4 to 8 to 12 g/day.
Methods: With TG >500 mg/dl despite Type V diet, hyperinsulinemia and diabetes control, and fibric acids, Lovaza
(4 g/d) was added for 1 month, and if TG remained >500 mg/dl, increased to 8 g/d for 1 month, and then to 12 g/
d for 1 month, and subsequently reduced to 4 g/day for 4 months.
Results: Primary HTG, median TG 884 mg/dl, 14 men, 1 woman, all white, age 50 ± 7 years, 12 non-diabetic, 3 with
stable diabetes control. Weight and diet held stable throughout. In 5 patients, after 1, 2, and 3 months on 4 g/day,
TG fell <500, mean 1390 to 234 (−83%, p<.0001), to 135 (−90%, p<.0001), and 158 mg/dl (−89%, p<.0001), with a
negative TG slope, p=.0013. Non-HDLC fell from 320 to 177 (−45%, p=.001), to 152 (−53%, p=.0002), and to 163
(−49%, p=.0004), with a negative slope, p=.01. In 10 patients, with Lovaza increased from 4 to 8 to 12 g, 3 failed to
respond. In 7 of these 10 patients, TG fell 37% from 1075 to 672 on 4 g (p=.006), to 577 on 8 g (−46%, p=.0009),
and to 428 mg/dl (−60%, p<.0001) on 12 g/day, with a negative TG slope, p=.0018. TG on 12 g/day was lower than
on 8 g/day, p =.03. Non-HDLC fell from 245 to 217 mg/dl (−11%) on 4 g/day, to 203 (−17%, p=.01) on 8 g/day, and
to 192 (−22%, p=.003) on 12 g/day, with a negative slope, p=.016. Compared to pre-Lovaza baseline, no abnormal
measures developed in safety tests. The 4, 8, and 12 g/d Lovaza doses were well tolerated.
Conclusion: Titration of Lovaza from 4 to 8 to 12 g/d safely offers an effective way to lower TG beyond
conventional 4 g therapy.
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Omega-3 fatty acids of marine origin are safe, effective tri-
glyceride (TG)-lowering agents [1-4], and are therapeutic
in combined hyperlipidemia when added to statins [5]. Al-
though the usual dose of the omega-3 marine long chain
polyunsaturated fatty acid preparation (Lovaza) is 4 g/day,
our previous studies [6-8] have shown that in patients re-
ceiving conventional triglyceride lowering regimens plus
4 g per day of Lovaza, further elevation of Lovaza to 8 g,* Correspondence: cjglueck@health-partners.org
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reproduction in any medium, provided the orand if necessary, to 12 g safely further lowers TG. Overall,
there appears to be a generally linear decrease in TG with
increasing dose of Lovaza [7]. In other studies of hypertri-
glyceridemic patients, intake of 4.5, 7.5, and 12 g omega-3
fatty acids have been used effectively over short treatment
durations [9-12].
There are many patients with primary and familial
hypertrigyceridemia (HTG) where conventional treat-
ment with diet, avoidance of alcohol, fibric acids, dia-
betes control, metformin (for hyperinsulinemia) [13],
and 4 g/day Lovaza fails to lower TG below 500 mg/dl,
with TG levels remaining well above the therapeuticLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Panel-III guidelines, TG >500 was identified as severe,
and a target for intervention, while an optimal TG level
was <150 mg/dl [14]. To the best of our knowledge there
is no published data which indicates that systematic
stepwise increments of Lovaza to 8 or 12 g per day
would have therapeutic effectiveness in further normali-
zing TG in subjects on conventional TG lowering regi-
mens which include Lovaza 4 g/day. We hypothesized,
based on our clinical experience [6-8], that increasing
Lovaza to 8 and then (if necessary) to 12 g/day would
safely further lower TG in subjects with severe primary
HTG who failed to lower TG below 500 mg/dl on con-
ventional therapy including Lovaza 4 g/day.
Our specific aim in the current study was to assess
effectiveness and safety of Lovaza 4, 8, and 12 g/day in
15 patients who were referred to us with primary HTG
(TG>1000 mg/dl) and failed to lower TG below 500 mg/dl
despite treatment with diet, avoidance of alcohol, fibric
acids, treatment of type 2 diabetes mellitus, and, in the
presence of hyperinsulinemia, metformin [13].
Results
There were 14 men, 1 woman, all white, mean age 50,
baseline mean ± SD TG 1251 ± 671 mg/dl, with 25th,
50th and 75th percentile TG of 791, 884, and 1640 mg/dl,
Table 1. Baseline mean ± SD HDL cholesterol was 29 ±
9 mg/dl and non-HDLC was 274 ± 104 mg/dl, Table 1.
Of the 3 subjects with type 2 diabetes, hemoglobin
A1C (HbA1C) was held stable below 7.2% throughout
the study period in 2, while in the third subject, mean
HbA1C was 8.2%, but stable throughout the study. All
patients with type 2 diabetes were treated with metfor-
min 2.5 g/day. Of the 12 non-diabetic patients, 5 had
impaired fasting glucose (≥ 100 mg/dl, 3 of these 5 had
hyperinsulinemia), and another 5 patients had hyperin-
sulinemia (>24.9 uU/ml). All of these 10 patients were
treated with branded Metformin 2.5 g/day.Table 1 Baseline Lipids, lipoproteins, and APO E genotype in
Mean ±SD
Age (years) 50 ±7
TG (mg/dl) 1251 ± 671
Total cholesterol (mg/dl) 303 ± 107
HDLC (mg/dl) 29 ± 9
Non-HDLC (mg/dl) 274 ± 104
APOE genotype 2-3
Responders n=12 2 (17%)
Non-responders n=3 0
Total n=15 2/15 (13%)
APOE 3–4 was more common in non-responders, Fisher’s p=. 04.Two subjects had ApoE 2–3 heterozygosity, 1 ApoE
2–4, 6 were homozygous for the wild-type normal geno-
type (ApoE 3–3), and 6 were ApoE 3–4 heterozygotes,
Table 1. ApoE 3–4 was more common in non-
responders (TG >500 mg/dl despite 12 g Lovaza),
Fisher’s p=.04, Table 1. All 3 patients who failed to have
sustained consistent reductions in TG below 500 mg/dl
as Lovaza was increased from 4 to 8 to 12 g/day (non-
responders) had the ApoE 3–4 genotype, Table 1.
After 1 month on 4 g/day Lovaza, in 5 patients, TG
fell well below 500 mg/dl, from a baseline mean of
1390 mg/dl on conventional TG-lowering therapy to
234 mg/dl (mean reduced 83%, p<.0001), Figure 1,
Table 2. Mean TG fell 90% to 135 mg/dl and to 158 mg/dl
(−89%) after 2 and then 3 months on Lovaza 4 g/day
(p<.0001 for both), with a negative slope as TG fell,
p=.0013, Table 2. In this group of 5 patients, mean TG
<200 mg/dl was maintained over 6 months treatment with
4 g/day Lovaza, Figure 1, Table 2. Mean non-HDL choles-
terol fell from 320 to 177 mg/dl (decreasing 45%, p=.001)
to 152 (−53%, p=.0002) to 163 mg/dl (−49%, p=.0004),
Table 2. In these 5 patients, on 4 g/day Lovaza compared
to baseline, there were no changes in body weight (p>.05),
a single month period with lower systolic blood pressure
(p=.04), and lower diastolic blood pressure (p=.05) in 2 of
the 7 months on Lovaza, Table 3. In these 5 patients, there
was no significant correlation between reduction in body
weight (median 216 falling to 214) and reduction in TG
(median 1170 mg/dl falling to 227 mg/dl) from visit 0 to
visit 1, Spearman correlation r= −.22, p>0.5.
Of the 10 patients (baseline mean TG 1163 mg/dl on
conventional TG-lowering therapy), as Lovaza was
increased from 4 to 8 to 12 g/day, 3 failed to consist-
ently respond, with mean TG at baseline 1369 mg/dl,
and after 3 months 1260 mg/dl while on Lovaza 12 g/day,
Figure 2, Table 4. One of these three non-responders was
the subject with type 2 diabetes whose mean HbA1C









1 (8%) 6 (50%) 3 (25%)
0 0 3 (100%)
1/15 (7%) 6/15 (40%) 6/15 (40%)
Figure 1 Five subjects whose triglyceride levels fell below 500 mg/dl on 4 grams of Lovaza/day.
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rose to 697 on 8 g/day, and rose further to 1141 mg/
dl on 12 g/day, Figure 2. Then, when Lovaza was
reduced to 4 g/day, TG rose to 2530 mg/dl, Figure 2.
In this group of 3 patients, body weight was lower
(p=.02) at one of the 7 visits on Lovaza, without sig-
nificant changes in systolic or diastolic blood pres-
sure, Table 3.
In 7 patients who responded with TG lowering as
Lovaza was increased to 12 g/day, Figure 3, Table 5, TG
fell from a baseline mean on conventional TG lowering
therapy of 1075 to 672 mg/dl on Lovaza 4 g/day (de-
creasing 37%, p=.006), to 577 on 8 g/day (46%, p=.0009),
and to 428 mg/dl on 12 g/day (60%, p <.0001), Table 5,
with a negative TG slope, p=.0018, Table 5. At the same





Mean ± SD median % change from Visit 0 p (vs Vi
0 0 1390 ±766 1170
1 4 234 ±97 227 −83% <.0001
2 4 135 ±71 107 −90% <.0001
3 4 158 ±51 142 −89% <.0001
4 4 164 ±48 155 <.0001
5 4 180 ±96 144 <.0001
6 4 194 ±166 114 <.0001
7 4 179 ±120 136 <.0001
TG decreasing slope during the first 3 months, when dose
changed from 0 to 4 g/day, p=.0013fell 17% to 203 mg/dl (p=.01), and fell 22% to 192 mg/dl
(p=.003), Table 5. In this group of 7 patients, body
weight was lower (p=.002) at the last of 7 visits on
Lovaza, systolic blood pressure was lower in one visit
(p=.05), and diastolic blood pressure lower at 2 visits
(p=.05, p=.02), Table 3. In 3 of these 7 patients after
1 month on 8 g/day Lovaza, TG levels had fallen to
<500 mg/dl (to 440, 422, and 371 mg/dl), but their
Lovaza was increased to 12 g/day, rather than being
retained for 1 month at 8 g/day.
Of the 12 subjects without type 2 diabetes, 5 of whom
had impaired fasting glucose (3 of these 5 had hyperin-
sulinemia), and 5 had hyperinsulinemia without IFG. All
10 patients were treated with metformin 2.5 g/day.
Changes in weight, insulin and glucose were not signifi-
cant (all p>0.6) from visit 0 to visit 1, and there was nosubjects, where the Lovaza sequence was 4,4,4,4,4,4,4
Non-HDLC (mg/dl)
sit 0) Mean ± SD median % change from Visit 0 p (vs Visit 0)
320 ±134 253
177 ±65 201 −45% .001
152 ±10 147 −53% .0002
163 ±19 171 −49% .0004
162 ±34 169 .0004
170 ±44 151 .0007
156 ±36 159 .0005
139 ±30 148 .0004
Non-HDLC decreasing slope during the first 3 months, when
dose changed from 0 to 4 g/day, p=.01
Table 3 Body weight and blood pressure at each visit in 5 subjects, where the Lovaza sequence was 4,4,4,4,4,4,4 g/day
Visit Dose Body weight (lb) Systolic BP (mmHg) Diastolic BP (mmHg)
Mean ± SD median p vs Visit 0 Mean ± SD median p vs Visit 0 Mean ± SD median p vs Visit 0
0 0 209 ±51 216 126 ±19 120 86 ±14 80
1 4 202 ±54 214 116 ±15 110 75 ±11 80 .05
2 4 202 ±51 214 110 ±7 110 .04 77 ±8 80
3 4 199 ±49 211 116 ±14 110 78 ±13 76
4 4 199 ±50 209 121 ±17 130 74 ±10 78 .05
5 4 202 ±51 214 122 ±13 118 78 ±5 80
6 4 201 ±60 225 122 ±2 122 77 ±6 80
7 4 201 ±59 224 120 ±12 116 77 ±6 77
In 7 subjects, where the Lovaza sequence was 4, 8, 12, 4, 4, 4,4 g/day
Visit Dose Body weight (lb) Systolic BP (mmHg) Diastolic BP (mmHg)
Mean ± SD median p vs Visit 0 Mean ± SD median p vs Visit 0 Mean ± SD median p vs Visit 0
0 0 251 ±30 246 138 ±28 124 88 ±13 86
1 4 251 ±31 246 139 ±25 132 88 ± 9 86
2 8 253 ±28 247 129 ±23 124 85 ±18 78
3 12 250 ±29 242 122 ±10 122 84 ±17 80
4 4 250 ±31 242 121 ±12 120 .05 79 ± 8 80 .05
5 4 251 ±29 249 130 ±16 130 85 ±12 82
6 4 247 ±33 244 136 ±24 132 83 ±14 80
7 4 243 ±34 235 .002 132 ±24 124 78 ±12 76 .02
In 3 non-responders, where the Lovaza sequence was 4, 8, 12, 4, 4, 4, 4 g/day
Visit Dose Body weight (lb) Systolic BP (mmHg) Diastolic BP (mmHg)
Mean ± SD median p vs Visit 0 Mean ± SD median p vs Visit 0 Mean ± SD median p vs Visit 0
0 0 204 ±10 204 121 ±17 120 84 ±4 85
1 4 202 ±11 196 115 ±15 110 77 ±7 76
2 8 198 ±14 191 122 ±3 120 87 ±6 90
3 12 200 ±14 195 125 ±8 120 82 ±5 84
4 4 198 ±13 192 113 ±12 120 76 ±4 75
5 4 196 ±12 190 .02 126 ±14 134 79 ±10 77
6 4 204 ±11 204 129 ±1 129 82 ±0 82
7 4 202 ±19 202 123 ±24 123 82 ±11 82
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TG from visit 0 to visit 1, p >0.6.
In the 15 patients, there were 85 patient-months on
Lovaza 4 g/day, 10 patient- months on 8 g/day, and 10
patient-months on 12 g/day. Compared to pre-Lovaza base-
line, no abnormal measures developed in laboratory safety
tests (p>0.1) on 4, 8, or 12 g/day Lovaza therapy. The 4, 8,
and 12 g/d Lovaza doses were well tolerated, and adherence
by pill count was >95% for all treatment groups.
Discussion
In the current study, after treating HTG with a conven-
tional TG-lowering regimen (fibric acids, diet, diabetes
control, and metformin, when hyperinsulinemic), 5
patients were very sensitive to addition of 4 g Lovaza/
day, with mean TG falling 90% from 1390 mg/dl to135 mg/dl and mean non-HDLC falling 53% from 320 to
152 mg/dl in 2 months. Moreover, at 2 of 7 monthly vi-
sits on Lovaza, diastolic blood pressure was lower than
at baseline, an additional beneficial outcome.
In 10 patients with mean TG 1163 mg/dl despite con-
ventional TG-lowering therapy, 3 patients (baseline
mean TG 1369 mg/dl) failed to respond significantly to
sequential increments of Lovaza from 4 to 8 to 12 g/day.
In 7 of these 10 patients, however, TG fell 37% from
1075 mg/dl to 672 mg/dl on Lovaza 4 g/day, fell 46% to
577 mg/dl on 8 g/day, and fell 60% to 428 mg/dl on
12 g/day, with a negative TG slope. At the same time,
mean non-HDLC fell 11% from 245 to 217 mg/dl, 17%
to 203 mg/dl, and 22% to 192 mg/dl. Moreover, diastolic
blood pressure was lower than baseline at last visits on
Lovaza.
Figure 2 Three subjects whose triglyceride levels failed to fall below 500 mg/dl despite titration of Lovaza from 4 to 8 to 12 grams/day.
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sponsive to Lovaza therapy, congruent with the report
by Christidis et al. [15] where triglyceride reduction on
fenofibrate was less marked in patients with the ApoE4
allele.
Titration of the Lovaza to 8 g/day (10 patient-months)
and 12 g/day (10 patient- months) in 10 patients did not
adversely affect any laboratory safety tests, did not pro-
duce petechiae or purpura, and was well tolerated. This
is a limited experience, however, with regard to safety of
8 and 12 g/day of Lovaza, and is a limitation of the
current study.
Another limitation of the current study was the failure
to measure plasma, red blood cell, and leukocyte fatty
acid profiles and compare these with the patients’
responses to the stepwise increases in doses of Lovaza.
Our findings in the current study are congruent with
previous studies in hypertriglyceridemic patients givenTable 4 TG and Non-HDLC at each visit during treatment In 3




Mean ± SD median p
0 0 1369 ±950 859
1 4 970 ±328 1154
2 8 1086 ±348 1190
3 12 1260 ±108 1290
4 4 1693 ±816 1650
5 4 1233 ±255 1360
6 4 1522 ±1065 1060
7 4 1760 ±71 1760up to 15 g/day of omega-3 fatty acids [6-12]. Harris
et al. [9] gave 4.5,7.5, and 12 g/d of omega-3 fatty acids
for 3 successive 6 week periods to 10 hypertriglyceri-
demic patients, and triglycerides fell from 540 to 257 to
248 to 208 mg/dl as the dose increased, p<.01 versus
baseline for each. In 22 women with median entry trigly-
cerides 1087 mg/dl, Goldenberg et al. [7] safely titrated
omega-3 fatty acids up to 12 g/day, with triglycerides
falling to a median of 326 mg/dl. In 4 women whose ini-
tial triglyceride levels were >750 mg/dl despite conven-
tional triglyceride-lowering therapy, Glueck et al. [8]
safely titrated omega-3 fatty acids up to 15 g/d. Sanders
et al. [10] safely treated 5 patients with primary hypertri-
glyceridemia with 15 g/d of omega-3 fatty acids over a
4 week period with mean triglyceride levels falling from
1147 to 558 mg/dl.
A triglyceride concentration above 1,000 mg/dl is an
indication for therapy to lower the risk of acutenon-responders, where the Lovaza sequence was 4, 8,12,
Non-HDLC (mg/dl)









Figure 3 Seven subjects whose triglyceride levels fell as Lovaza was titrated from 4 to 8 to 12 grams/day.
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1,000 mg/dl the indication for treatment is primarily to
reduce the risk of clinical events caused by atheroscle-
rosis [7,8,16-18]. The relationship between hypertrigly-
ceridemia and coronary heart disease is abolished when
non-HDL cholesterol and HDL cholesterol concentra-
tions are controlled for [19].
Omega-3 fatty acids have successfully been used in
treatment of severe primary HTG [7,20,21]. Omega-3
fatty acids and fenofibrate have similar TG-lowering
effects and promote similar changes in endothelium-
dependent dilation, but fenofibrate therapy has substan-
tially better effects on lipoprotein and metabolic profiles
in patients with HTG [22]. In severe HTG, fibric acids




Mean ± SD median % change,
p vs Visit 0
p* (vs former V
0 0 1075 ±525 857
1 4 672 ±247 587 −37%, .006
2 8 577 ±189 666 −46%, .0009 NS
3 12 428 ±184 443 −60%, <.0001 .03
4 4 561 ±244 554 .0006 .03
5 4 538 ±115 593 .0004
6 4 459 ±171 502 <.0001
7 4 430 ±191 395 <.0001
TG decreasing slope during the first 3 months, when the Lo
dose was increased from 0 to 12 g/day, p=.0018
p: comparison of Least-square means using Mixed model.
p*: paired Wilcoxon test for the change from Visit 1 to Visit 2 (dosage from 4 g/day
(dosage from 12 g/day to 4).[7,8,23,24]. In the current study, we did not add nicoti-
nic acid to the entry conventional TG lowering regimen
(low fat diet [<25% of calories as fat], fibric acids, met-
formin reduction of insulin resistance, diabetes control)
to avoid worsening [25-28] of type 2 diabetes, conversion
of impaired fasting glucose to levels ≥126 mg/dl, or wor-
sening insulin resistance-hyperinsulinemia in patients with
antecedent hyperinsulinemia.
Bays et al. [21] carried out a placebo-controlled rando-
mized study of 229 diet-stable patients with fasting TG
≥ 500 mg/dl and ≤ 2,000 mg/dl. Mean baseline TG levels
were 680, 657, and 703 mg/dl for eicosapentaenoic acid
ethyl ester (AMR101) 4 g/day, AMR101 2 g/day, and
placebo. AMR101 4 g/day reduced the placebo-
corrected TG levels by 33.1% (p <.0001) and AMR101quence was 4, 8, 12, 4, 4, 4, 4 g/day
Non-HDLC (mg/dl)
isit) Mean ± SD median % change,
p vs Visit 0
p* (vs former Visit)
245 ±88 214
217 ±62 223 −11%,
203 ±44 199 −17%, .01 NS
192 ±61 164 −22%, .003 NS
203 ±49 185 .01 NS
205 ±44 233 .01
189 ±31 185 .001
171 ±43 164 .0002
vaza Non-HDLC decreasing slope during the first 3 months, when the
Lovaza dose was increased from 0 to 12 g/day, p=.016
to 8); from Visit 2 to Visit 3 (dosage from 8 g/day to 12); from Visit 3 to Visit 4
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TG levels >750 mg/dl, AMR101 4 g/day reduced the
placebo-corrected TG levels by 45.4% (p =.0001) and
AMR101 2 g/day by 32.9% (p =.0016). AMR101 signifi-
cantly reduced non-HDLC.
Another approach to the stepped management of the
type of severely hypertriglyceridemic patients described
in this report would be to lower TG to < 1,000 mg/dL
with Lovaza, and then add atorvastatin, 80 mg/day, or
rosuvastatin, 40 mg/day [29].
Conclusion
In patients with severe primary HTG despite conven-
tional TG lowering therapy, addition of Lovaza 4 g per
day, and where necessary, increasing to 8 or 12 g per
day safely further lowers TG in a linear fashion.
Methods
Study design, patients
The study followed a protocol approved by the Jewish
Hospital IRB, with signed informed consent, and after
an entry visit, included 8 subsequent visits at monthly
intervals. Patients were instructed in a eucaloric diet
with total fat restricted to no more than 25% to 30% of
calories [30] at the entry visit by registered dietitians,
with no alcohol intake. At each monthly visit, dietary ad-
herence was reviewed by the dietitians, using 24-hour
recall. Weight loss was not a targeted goal during the 8-
month treatment period.
Inclusion criteria
Inclusion criteria included primary HTG [18] with fast-
ing TG levels >1000 mg/dl, and persistence of TG levels
> 500 mg/dl despite conventional TG lowering therapy
for 1 month, including diet, control of type 2 diabetes
mellitus, fibric acids, and, where indicated, metformin
for treatment of hyperinsulinemia. Type 1 diabetics were
excluded; three type 2 diabetics with stable hemoglobin
A1C control were included.
Exclusion criteria
1. Patients with known allergy to fish.
2. HTG secondary to alcoholism, exogenous
corticosteroids or estrogens, nephrotic syndrome,
hemochromatosis, glycogen storage disease,
uncontrolled diabetes, Cushing’s syndrome, uremia.




After an overnight fast, blood was obtained for entry
measurement of lipid profile, complete blood count,fasting glucose, hemoglobin A1C (HbA1C), insulin, C-
peptide, renal and liver function tests, T4 and TSH, and
apo E genotype. At each of 8 subsequent visits, blood
was drawn for lipid profile, complete blood count, glu-
cose, HbA1C, renal and liver function, insulin, and C
peptide. At entry, and at each subsequent visit, dermato-
logic examinations were carried out to record any pe-
techiae or bruising. At entry, and at 8 subsequent visits,
weight and blood pressure were measured, and a brief
physical exam was carried out. At each visit, adherence
to the targeted Lovaza dose was assessed by pill count,
and adherence to diet by a 24-hour diet recall.Lovaza Dose Schedule, serial monthly visits
Visit −1 (Entry)
Patients referred to our center with TG >1,000 mg/dl
were instructed in a eucaloric diet with total fat
restricted to no more than 25% to 30% of calories [30],
with alcohol restricted to zero. If the patient was not
already taking fenofibrate 145 mg/day or gemfibrozil
1.2 g/day, these therapies were instituted. All the 3
patients with type 2 diabetes received metformin 2.5 g/
day, and one (with HbA1C >7.2%) also received liraglu-
tide 1.8 mg/day. Nicotinic acid was not used since many
of the patients either had type 2 diabetes mellitus, or
impaired fasting glucose, or hyperinsulinemia which
were relative contraindications [25-28] to its use.
Patients with impaired fasting glucose and/or fasting
hyperinsulinemia (>24.9 uU/ml) were also treated with
metformin [31,32], 2.5 g/day.Visit 0 (Baseline)
One month after visit −1, if TG remained >500 mg/dl
despite conventional TG lowering therapy, then patients
were instructed to start Lovaza, 2 g with breakfast, 2 g
with the evening meal, while continuing their antecedent
TG lowering therapy unchanged, and dietary instruction
was reinforced.Visit 1
One month after visit 0, if TG had fallen to < 500 mg/dl,
Lovaza was held at 4 g/day. If TG remained >500 mg/dl,
Lovaza was increased to 8 g/day, with other components
of the TG lowering regimen held stable throughout.Visit 2
One month after visit 1, if TG had fallen to < 500 mg/dl
on 8 g/day, the Lovaza dose was kept at 8 g/day, but if
TG remained > 500 mg/dl, Lovaza was increased from 8
to 12 g per day, with other components of the TG lower-
ing regimen held stable.
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One month after visit 2, Lovaza was diminished in all
patients to 4 g/day.
Visits 4–7
Four monthly visits after visit 3; Lovaza kept at 4 g/day.
Statistical analysis
All statistical analysis was done using SAS 9.1.3.
For each treatment group (according to Lovaza dosage
sequences), mean ± SD and median TG, non-HDLC,
body weight and blood pressure (BP) at each visit were
calculated. Changes from baseline to follow-up were
tested using MIXED model, with visit as fixed effect,
subject as random effect, and comparison of least square
means (SAS proc MIXED).
For each treatment group, MIXED model for TG was
constructed for the first 3 months on Lovaza, fixed effect
was time (visit order), random effect was subject, with
repeated measures had AR(1) variance structure. Using
MIXED model, the TG slope was assessed.
Paired Wilcoxon tests were used to assess the effect of
changes of Lovaza dosage (from 4 to 8 g/day, from 8 to
12 g/day, from 12 to 4 g/day) on TG and non-HDLC.
Abbreviations
(HTG): Primary hypertriglyceridemia; (TG): triglyceride; (HDLC): high density
lipoprotein cholesterol; (non-HDLC): non high density lipoprotein cholesterol.
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